SFX by Ex Libris Inc.

Title:	Resolving genetic heterogeneity in cancer
Source:	Nature Reviews Genetics [1471-0056] Samra Turajlic, Andrea yr:2019

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Zhou, L. "Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level." BMC Cancer (2019): 369-369.
description	2.	"Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints." Cancer letters. 458: 13-20.
description	3.	Ben David, U. "Genomic evolution of cancer models: perils and opportunities." Nature reviews. 19.2: 97-109.
description	4.	Winters, Ian P. "Towards quantitative and multiplexed in vivo functional cancer genomics." Nature reviews. 19.12: 741-755.
description	5.	Kim, T. "Subclonal genomic architectures of primary and metastatic colorectal cancer based on intratumoral genetic heterogeneity." Clinical cancer research 21.19 (2015): 4461-4472.
description	6.	Gillis, J. "Predictability of human differential gene expression." Proceedings of the National Academy of Sciences of the United States of America (2019): 6491-6500.
description	7.	Berger, Michael F. "The emerging clinical relevance of genomics in cancer medicine." Nature Reviews Clinical Oncology 15.6 (2018): 353-365.
description	8.	Patel, Shashank J. "Identification of essential genes for cancer immunotherapy." Nature 548.7669 (2017): 537-542.
description	9.	Curtis, C. "A Big Bang model of human colorectal tumor growth." Nature Genetics 47.3 (2015): 209-216.
description	10.	Manguso, Robert T. "In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target." Nature. 547.7664: 413-418.
description	11.	Sun, R. "Between-region genetic divergence reflects the mode and tempo of tumor evolution." Nature Genetics 49.7 (2017): 1015-1024.
description	12.	Kang, H. "Many private mutations originate from the first few divisions of a human colorectal adenoma." The Journal of pathology 237.3 (2015): 355-362.
description	13.	Fearon, E R R. "A genetic model for colorectal tumorgenesis." Cell 61.5 (1990): 759-767.
description	14.	Valkenburg, Kenneth C. "Targeting the tumour stroma to improve cancer therapy." Nature Reviews Clinical Oncology 15.6 (2018): 366-381.
description	15.	Jacob, Howard J. "Molecular modeling in the age of clinical genomics, the enterprise of the next generation." Journal of Molecular Modeling 23.3 (2017): 1-14.
description	16.	Powles, T. "Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial." The lancet. 391.10122: 748-757.
description	17.	Hackl, H. "Computational genomics tools for dissecting tumour–immune cell interactions." Nature Reviews. Genetics 17.8 (2016): 441-458.
description	18.	Kepp, O. "eIF2α phosphorylation as a biomarker of immunogenic cell death." Seminars in cancer biology 33.C (2015): 86-92.
description	19.	Hellmann, Timothy N. "Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer." Science 348.6230 (2015): 124-8.
description	20.	Sottoriva, A. "Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics." Proceedings of the National Academy of Sciences of the United States of America 110.10 (2013): 4009-4014.